Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors
← catalyst calendarSponsored by Seagen, a wholly owned subsidiary of Pfizer (industry) · PFE — their whole pipeline →. With Genmab, Merck Sharp & Dohme LLC.
Phase
Phase 2
Status
Active, not recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
350actual
Sites
175
Countries
Canada, France, Germany +4
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2018-06-25 | actual | When the study began enrolling |
| Primary completion | 2026-03-20 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-03-31 | estimated | The whole study's end, after follow-up |
| First posted | 2018-04-02 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-22 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Colorectal Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Exocrine Pancreatic Cancer
- Carcinoma, Squamous Cell of Head and Neck
Interventions
- Drug: tisotumab vedotin — also filed as TIVDAK
- Drug: pembrolizumab — also filed as KEYTRUDA®
- Drug: carboplatin
- Drug: cisplatin
Primary outcome
what the primary-completion date above is the date OFConfirmed Objective Response Rate (ORR) (Parts A, B, C, D, E, F, and G)
measured Up to approximately 3 years
Publications
- PMID 41044356 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed